



## **Jitsubo Enters into a Collaboration with Neuland for Peptide Synthesis**

**Tokyo, March 5, 2018** - Jitsubo Co., Ltd. (Head Office: Yokohama, Kanagawa; President and CEO: Kazuaki Kanai) today announced that it has entered into a strategic collaboration in peptide research with Neuland Health Sciences Private Limited (“NHSPL”), an India-based Peptide API Research company belonging to Neuland Group having 34 years of heritage. A Memorandum of Understanding was signed on March 5, 2018, with the goal of establishing a long-term partnership focusing on research and commercial development in the field of peptide APIs.

“Jitsubo’s Molecular Hiving technology can bring about a strong cost advantage. Combining Jitsubo’s Molecular Hiving technology with Neuland’s specialized purification technology and peptide capabilities, we aim at jointly developing peptide APIs. We recognize clear competitive advantages of the partnership in the growing peptide market. This collaboration, which is a mutually complementary relationship, implies a huge potential”, said Kazuaki Kanai, CEO of Jitsubo.

“We are seeing an increasing demand for value-added peptides and for peptides incorporating non-natural amino acids.” said Davuluri Saharsh Rao, Director, NHSPL. “The goal of our collaboration is to contribute to the global healthcare industry by providing high-quality but affordable peptides to the market. I am confident that this global alliance between a Japanese company with a high technological edge and an Indian company with extensive experience and capabilities in peptide will create a great synergy.”

Further, the Jitsubo-Neuland partnership creates opportunity for an exploratory research and development collaboration in peptide where Jitsubo’s Molecular Hiving technology could be complementary to Neuland’s strength in peptide manufacturing (using Solid, Solution, Hybrid phase) and its proprietary purification technology.

### **About Neuland**

Neuland is a 34 years old pharmaceutical group headquartered in Hyderabad, India, with offices in the U.S. and Japan and has over a decade of experience in peptide research. Its peptide capabilities extends from solid phase, solution phase and hybrid phase peptide

synthesis to a proprietary purification technology, a preparative HPLC technique which is 10 to 20x better in throughput compared to the standard preparative HPLC technique.

For more information on Neuland, visit: [www.neulandlabs.com](http://www.neulandlabs.com)

**Neuland Contact:**

Japan Office

Tel: +81 3 3526 5171

Email: [neulandjp@neulandlabs.com](mailto:neulandjp@neulandlabs.com)

India Corporate Office

Tel: +91 40 3021 1600

Email: [neuland@neulandlabs.com](mailto:neuland@neulandlabs.com)

**About Jitsubo Co., Ltd.**

Jitsubo has a mission to enrich the world with smiles and is aiming to become a world class R&D-focused pharmaceutical company that provides solutions to patients using its proprietary peptide-related technologies. Our goals are to address unmet medical needs and administer to the sustainable development of medical care. We pursue these objectives through Molecular Hiving™ (a novel technology to synthesize peptides in high-quality and at lower costs compared to existing methods) and Peptune™ (a peptide structure engineering technology that develops focused peptide libraries during drug discovery). Jitsubo was acquired by the Sosei Group, an international biopharmaceutical drug development company, in December 2014, and enjoys invaluable support in both R&D and global network.

For further information, please visit: [www.jitsubo.com](http://www.jitsubo.com)

**Jitsubo Contact:**

Tel : +81-(0) 45-633-4327

Email: [info@jitsubo.com](mailto:info@jitsubo.com)